Use of oncolytic adenovirus for cancer treatment;Uso de adenovirus oncolíticos para el tratamiento del cáncer

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 32, Issue SUPPL. A, 2010, Pages 3-7

  Cascallo M ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; DRUG EFFICACY; PHARMACODYNAMICS; VIRUS GENOME; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; GENE THERAPY; GENETICS; HUMAN; NEOPLASM; ONCOLYTIC VIROTHERAPY; VIROLOGY;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

EID: 79954436839     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2010.32.1.1444424     Document Type: Article

References (12)

1. Liu, T.C., Galanis, E., Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4:101-17.
2. Alemany, R., Cascallo, M. Oncolytic viruses from the perspective of the immune system. Future Microbiol 2009; 4:527-36.
3. Alemany, R. Cancer selective adenoviruses. Mol Aspects Med 2007; 28:42-58.
4. Alonso, M.M., Cascallo, M., Gomez-Manzano, C., et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 2007; 67:8255-63.
5. Cascallo, M., Alonso, M.M., Rojas, J.J., Perez-Gimenez, A., Fueyo, J., Alemany, R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 2007; 15:1607-15.
6. Sherr, C.J. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2:731-7.
7. Alonso, M.M., Gomez-Manzano, C., Jiang, H., et al. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced antiglioma effect in vivo. Cancer Gene Ther 2007; 14:756-61.
8. Shayakhmetov, D.M., Gaggar, A., Ni, S., Li, Z.Y., Lieber, A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79:7478-91.
9. DeWeese, T.L., van der Poel, H., Li, S., et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61:7464-72.
10. Jang, S.H., Wientjes, M.G., Lu, D., Au, J.L. Drug delivery and transport to solid tumors. Pharm Res 2003; 20:1337-50.
11. Guedan, S., Rojas, J.J., Gros, A., Mercade, E., Cascallo, M., Alemany, R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010; in press.
12. Baumgartner, G., Gomar-Hoss, C., Sakr, L., Ulsperger, E., Wogritsch, C. The impact of extracellular matrix on the chemoresistance of solid tumors - experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 1998; 131:85-99.